AbbVie

AbbVie

Yahoo Finance • yesterday

AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease

AbbVie ABBV announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking approval for its blockbuster immunology drug, Skyrizi (risankizumab), for subcutaneous (SC) induction in adult patients wit... Full story

Yahoo Finance • 2 days ago

Slate Medicines Starts Migraine Treatment Study

By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company's subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending do... Full story

Yahoo Finance • 2 days ago

3 Dividend Stocks, 12 Paychecks a Year: How to Get Paid Every Month

Quick Read Altria (MO) and Chevron (CVX) anchor a three-stock dividend ladder that blends to a 4% yield and delivers a paycheck every month. AbbVie's Skyrizi and Rinvoq each grew roughly 24% in Q2, fueling raised full-year EPS guidance an... Full story

Yahoo Finance • 2 days ago

FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now

In a significant development for Alzheimer's diagnostics, the U.S. Food and Drug Administration (FDA) has recently granted clearance to the Elecsys pTau217 blood test, developed jointly by healthcare giants Eli Lilly LLY and Roche RHHBY. T... Full story

Yahoo Finance • 2 days ago

AbbVie (ABBV) Filed For EU Crohn's Disease Label Expansion

AbbVie (NYSE: ABBV) has submitted a regulatory application to the European Medicines Agency for SKYRIZI (risankizumab) subcutaneous induction in adults with moderately to severely active Crohn's disease. The filing seeks to add a less inva... Full story

Yahoo Finance • 2 days ago

AbbVie files for EMA approval of Skyrizi for Crohn’s disease treatment

[AbbVie] hapabapa * AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]) on Thursday said that it has submitted an application to the European Medicines Agency seeking approval for SKYRIZI (risankizumab) for subcutaneous induction for t... Full story

Yahoo Finance • 2 days ago

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV) induction NORTH CHICAGO... Full story

Yahoo Finance • 3 days ago

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

The Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) provides broad, low-cost exposure to the entire healthcare sector, whereas the VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a concentrated, higher-yielding focus on global pharmaceuti... Full story

Yahoo Finance • 3 days ago

Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor

LeCause brings more than 30 years of senior leadership in eye care, joining Stuart to commercialize a new class of collagen-reparative therapeutics STUART, Fla., August 26, 2026--(BUSINESS WIRE)--Stuart Therapeutics, Inc. ("Stuart"), a la... Full story

Yahoo Finance • 4 days ago

How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?

AbbVie's ABBV oncology franchise continued to face pressure in the second quarter of 2026, primarily due to the ongoing decline in sales of the blood cancer drug Imbruvica. The company generated oncology revenues of $1.65 billion in the qu... Full story

Yahoo Finance • 4 days ago

LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?

Eli Lilly LLY and AbbVie ABBV are leading U.S. drugmakers with established portfolios, blockbuster therapies, robust R&D pipelines, large market capitalizations and a strong global presence. Both have significant exposure to major therapeu... Full story

Yahoo Finance • 4 days ago

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO RGNX stock plunged 24.9% on Monday after the FDA placed a clinical hold on its investigational one-time gene therapy, RGX-121, for the treatment of boys with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome.... Full story

Yahoo Finance • 4 days ago

2 S&P 500 Stocks with Exciting Potential and 1 We Brush Off

2 S&P 500 Stocks with Exciting Potential and 1 We Brush Off While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financial... Full story

Yahoo Finance • 5 days ago

Is AbbVie (ABBV) Quietly Rebalancing Its Growth Story Around Oncology Innovation?

Earlier in August 2026, AbbVie reported new clinical, translational and real-world data from its lung cancer portfolio at the World Conference on Lung Cancer, including high objective response rates and generally manageable safety profiles... Full story

Yahoo Finance • 5 days ago

Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

Spyre Therapeutics SYRE has built a broad clinical-stage pipeline across inflammatory bowel disease, rheumatic diseases and hidradenitis suppurativa. Multiple proof-of-concept readouts could broaden the opportunity, while its cash balance... Full story

Yahoo Finance • 5 days ago

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

Spyre Therapeutics SYRE expanded its inflammatory-disease strategy in August with SPY772 and the phase II SKYLIGHT study in hidradenitis suppurativa, or HS. The move takes its combination approach into a new disease area beyond inflammator... Full story

Yahoo Finance • 5 days ago

J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead

Johnson & Johnson's JNJ pipeline is becoming an increasingly important growth driver as the company looks to offset future pressure from mature products such as Stelara and eventually Darzalex. The company has a particularly strong set of... Full story

Yahoo Finance • 5 days ago

Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome. Continue Reading... Full story

Yahoo Finance • 5 days ago

SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?

Spyre Therapeutics SYRE has advanced 44.9% in the past three months, far outpacing the Zacks sub-industry's 11.7% gain and the S&P 500's 1.2% rise. That run has put the durability of the stock's momentum in focus. Positive ulcerative coli... Full story

Yahoo Finance • 6 days ago

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie Inc. (NYSE:ABBV) spent years preparing investors for the decline of Humira, once one of the best-selling medicines in the world. Its fiscal Q2 2026 results provide some of the clearest evidence yet that the company's replacement str... Full story